Neurocrine Biosciences
NBIX
302 hedge funds and large institutions have $7.51B invested in Neurocrine Biosciences in 2019 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 119 increasing their positions, 103 reducing their positions, and 53 closing their positions.
52% more call options, than puts
Call options by funds: $73.7M | Put options by funds: $48.6M
16% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 103
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
0% more ownership
Funds ownership: 97.45% → 97.45% (+0%)
4% less capital invested
Capital invested by funds: $7.8B → $7.51B (-$289M)
7% less funds holding
Funds holding: 325 → 302 (-23)
30% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$290M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$98.8M |
| 3 |
HM
HealthCor Management
New York
|
+$70.2M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$63M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$60.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$101M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$52.9M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$51.2M |
| 4 |
JP Morgan Chase
New York
|
-$49.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$33M |
NBIX Hedge Fund Activity: Q2 2019 in Review
302 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2019, worth a combined $7.51B — down 3.7% from $7.8B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of NBIX and 37 opened new positions — a net loss of 16 holders — while 103 trimmed existing stakes and 119 added.
The largest buyer was Bellevue Group, adding an estimated $290M. The largest seller was Fidelity Investments, cutting an estimated $101M.
- 302 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2019, down from 325 in Q1 2019.
- Funds reported $7.51B of Neurocrine Biosciences stock for Q2 2019, down 3.7% quarter-over-quarter.
- 37 funds opened new Neurocrine Biosciences positions in Q2 2019 and 53 closed out, a net change of -16 holders.
- The largest Neurocrine Biosciences buyer in Q2 2019 was Bellevue Group, an estimated $290M added.
- The largest Neurocrine Biosciences seller in Q2 2019 was Fidelity Investments, an estimated $101M sold.
Based on aggregated 13F filings for Q2 2019.